Achillion's Hepatitis C Drug Gets FDA Fast Track
January 5, 2012
New Haven, Conn.-based Achillion Pharmaceuticals announced that the Food and Drug Administration has granted fast-track designation to its experimental treatment for hepatitis C virus. The drug, ACH-1625, is currently in a mid-stage trial. Fast-track status expedites FDA's review of drugs intended to treat serious illnesses and fill unmet medical needs.
Alarming Incidence of Hepatitis C Virus Re-Infection After Treatment of Sexually Acquired Acute Hepatitis C Virus Infection in HIV-Infected MSM
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)